ArticleAging pathobiology and therapeutics2023
Resilience to aging drives personalized intervention strategies for Alzheimer's disease.
Article in Aging pathobiology and therapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
There has been little progress in reducing the incidence and mortality of Alzheimer's disease (AD). Prevention of onset, more accurate diagnostic tools, and prediction of health outcomes have all been identified as critical issues, but more and better basic research approaches are needed. The single greatest risk factor associated with AD is aging. It follows that if aging can be delayed, there should be an equivalent delay or even prevention of the onset of AD neuropathology. Therefore, targeting multiple pathways of aging would be a powerful way to enhance resilience to aging and slow or prevent the onset of AD neuropathology and dementia in a personalized manner. More effective and predictive animal models, such as the aging pet cat that spontaneously develops neuropathology similar to human AD patients, are necessary to help validate noninvasive and inexpensive biomarkers for identifying individuals at risk. Resilience to aging and its ability to delay or prevent the onset of age-related diseases should be the focus for preventing brain aging and enhancing resistance to AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.